In focus · trending topic

hepatitis C virus (HCV)

17 stories · following the connections

Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen

By Nasdaq OMXSep 11, 2017, 7:01 AM UTC

Achillion to Present at the 2017 JMP Securities Life Sciences Conference

By Nasdaq OMXJun 15, 2017, 8:05 PM UTC

Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs

By Nasdaq OMXMay 4, 2017, 10:05 AM UTC

Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference

By Nasdaq OMXMay 2, 2017, 10:05 AM UTC

Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178

By Nasdaq OMXApr 22, 2017, 7:00 AM UTC

Achillion Reports 2016 Fourth Quarter and Year-End Financial Results

By Nasdaq OMXFeb 23, 2017, 9:05 PM UTC

Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV

By Nasdaq OMXDec 28, 2016, 11:05 AM UTC

Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV

By Nasdaq OMXNov 30, 2016, 11:05 AM UTC